Nature Medicine retracted a widely publicized Chinese lung cancer study, “Lungtime-C01,” after concerns intensified about research integrity and data transparency. The paper had reported that administering immunotherapy before 3 p.m. in advanced non-small-cell lung cancer dramatically improved outcomes versus later dosing. The journal cited discrepancies raised by researchers, including differences between Chinese and English protocol versions and unexpected data patterns. It also said it no longer had confidence in the integrity of the results after additional data review, with evidence suggesting patient randomization on the treatment day was inconsistent with what is typically expected. For biotech and clinical development teams, the retraction reinforces how quickly practice-changing claims can unravel when trial conduct details and documentation do not stand up to scrutiny in high-impact peer review.